RxDoctor Payments Data

Carlos Fernandez Sifre, MD

Internal Medicine · San Juan, PRNPI 1306876867

Payments from drug & device makers

$3,313in general payments, 2019–2025

Across 153 payments — averaging $21.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$956
  • PBG Puerto Rico LLC$368
  • Johnson & Johnson$359
  • E.r. Squibb & Sons, L.L.C.$323
  • Novartis$50
  • plus $162 from 7 others

What the payments were for

  • Food & beverage$3,27599%
  • Education$181%
  • Gifts$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,313 in reported general payments places this provider in the 85th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$9,299
Medicare patients
24
Services billed
107

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanumetSitagliptin Phos/Metformin Hcl19$28,140
FarxigaDapagliflozin Propanediol17$23,662
TradjentaLinagliptin20$22,970
EliquisApixaban22$17,570
XareltoRivaroxaban20$16,739
OzempicSemaglutide16$15,571
JardianceEmpagliflozin14$12,139
SynthroidLevothyroxine Sodium131$10,592
Breo ElliptaFluticasone/Vilanterol13$5,296
Candesartan Cilexetil35$4,775
Mesalamine12$2,365
Atorvastatin Calcium185$2,260
Metoprolol Succinate91$1,411
LantusInsulin Glargine,hum.Rec.Anlog19$1,334
Losartan Potassium98$1,208

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanumet$12$28,14019 claims
AstraZenecaFarxiga$1,095$23,66217 claims
Johnson & JohnsonXarelto$359$16,73920 claims
AbbVieSynthroid$25$10,592131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →